12:00 AM
Dec 07, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Hycamtin topotecan hydrochloride regulatory update

The U.K.'s NICE issued guidance recommending the use of oral Hycamtin topotecan from GlaxoSmithKline only in patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >